The huoxiang zhengqi for COVID-19 market size has grown rapidly in recent years. It will grow from $1.54 billion in 2025 to $1.73 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to high reliance on traditional medicine during health crises, government endorsement of TCM during COVID-19, limited early pharmaceutical options, cultural preference for herbal remedies, rapid demand during pandemic waves.
The huoxiang zhengqi for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to continued interest in immune-support therapies, expansion of integrative medicine practices, rising health-conscious consumer base, growth of herbal pharmaceutical manufacturing, increasing research into traditional formulations. Major trends in the forecast period include growing acceptance of traditional chinese medicine, increasing use of herbal formulations for immune support, expansion of preventive healthcare applications, rising integration with conventional covid therapies, increasing demand for digestive and immune health remedies.
The rising demand for herbal medicine is expected to drive the growth of the Huoxiang Zhengqi for COVID-19 market in the coming years. Herbal medicine involves the use of plants or plant-derived substances for therapeutic purposes to prevent, treat, or manage health conditions. This growing demand is largely fueled by consumers’ preference for natural, plant-based remedies over synthetic drugs, due to perceived safety, fewer side effects, and holistic health benefits. Huoxiang Zhengqi for COVID-19 supports herbal medicine by offering a traditional remedy that enhances immune function, alleviates symptoms, and promotes recovery, highlighting the potential of herbal therapies in managing viral infections. For example, in September 2024, HerbalGram, a US-based nonprofit organization, reported that total annual sales of herbal dietary supplements increased from $12.018 billion in 2022 to $12.551 billion in 2023, reflecting a 4.4% growth. Consequently, the growing demand for herbal medicine is propelling the expansion of the Huoxiang Zhengqi for COVID-19 market.
Leading companies in the Huoxiang Zhengqi for COVID-19 market are focusing on innovative private-brand product launches, such as Huoxiang Zhengqi oral liquid formulations. These modernized liquid versions of the traditional Huoxiang Zhengqi herbal formula are designed to enhance convenience, ensure accurate dosing, and promote faster absorption. For example, in June 2024, YSB Inc., a China-based pharmaceutical retail and healthcare services company, launched the Leyaoshi Huoxiang Zhengqi Oral Liquid. The product features a ready-to-drink, single-dose liquid format, provides rapid digestive and anti-dampness support, and has a formulation optimized for seasonal gastrointestinal discomfort.
In August 2024, China Resources Sanjiu, a China-based provider of traditional Chinese medicines and pharmaceutical products, acquired a 28% stake in Tasly Pharmaceuticals for USD 8.75 billion (RMB 62.12 billion). This acquisition was intended to strengthen the company’s control over Tasly, enhancing its strategic capabilities in modern Chinese medicine innovation and integrated drug development. Tasly Pharmaceuticals is a China-based company specializing in modern traditional Chinese medicines, chemical drugs, and biopharmaceutical therapies.
Major companies operating in the huoxiang zhengqi for COVID-19 market are Yunnan Baiyao Group Co. Ltd., Beijing Tongrentang Co. Ltd., Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd., Tasly Pharmaceutical Group Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Guizhou Sanli Pharmaceutical Co. Ltd., China Shineway Pharmaceutical Group Limited, Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., Wuhu Zhanghengchun Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd., Sichuan Neo-Green Pharmaceutical Technology Co. Ltd., Hutchison China MediTech Limited, Shijiazhuang Yiling Pharmaceutical Co. Ltd., Jilin Aodong Pharmaceutical Group Co. Ltd., Livzon Pharmaceutical Group Inc., China Traditional Chinese Medicine Holdings Co. Ltd., Kunming Pharmaceutical Corp., Guangdong Yifang Pharmaceutical Co. Ltd., Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Asia-Pacific was the largest region in the Huoxiang Zhengqi for COVID-19 market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the huoxiang zhengqi for COVID-19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the huoxiang zhengqi for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the huoxiang zhengqi for COVID-19 market by increasing the cost of imported herbal raw materials, botanical extracts, and packaging components used in traditional formulations. These impacts have been most visible in liquid and granule product segments, particularly in export-driven Asia-Pacific markets. International distribution channels have faced pricing volatility due to trade barriers. However, tariffs have encouraged domestic cultivation of medicinal herbs and localized production, strengthening supply stability.
The huoxiang zhengqi for COVID-19 market research report is one of a series of new reports that provides huoxiang zhengqi for COVID-19 market statistics, including huoxiang zhengqi for COVID-19 industry global market size, regional shares, competitors with a huoxiang zhengqi for COVID-19 market share, detailed huoxiang zhengqi for COVID-19 market segments, market trends and opportunities, and any further data you may need to thrive in the huoxiang zhengqi for COVID-19 industry. This huoxiang zhengqi for COVID-19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Huoxiang Zhengqi for COVID-19 is a traditional Chinese herbal formula used to manage COVID-19 cases, especially when symptoms include gastrointestinal issues such as nausea, diarrhea, or fatigue caused by dampness. Its primary role is to expel dampness, relieve exterior syndromes, and support digestive and immune function. It is often used alongside antiviral and supportive therapies in traditional Chinese medicine protocols.
The main types of Huoxiang Zhengqi for COVID-19 include liquids, pills, granules, and other forms. Huoxiang Zhengqi liquid is designed to relieve digestive symptoms such as nausea, vomiting, and bloating by restoring balance to the stomach and spleen. Its users typically include health-conscious individuals, those seeking immune support, alternative medicine enthusiasts, and parents purchasing for their children. It is commonly applied for preventive health, symptom management during COVID-19, post-recovery care, and seasonal or illness-related protection. The product is used in hospitals, clinics, home care settings, and other healthcare environments.
The huoxiang Zhengqi for COVID-19 market consists of sales of syrups, powders, injections, essential oils, and nasal sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The huoxiang zhengqi for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to continued interest in immune-support therapies, expansion of integrative medicine practices, rising health-conscious consumer base, growth of herbal pharmaceutical manufacturing, increasing research into traditional formulations. Major trends in the forecast period include growing acceptance of traditional chinese medicine, increasing use of herbal formulations for immune support, expansion of preventive healthcare applications, rising integration with conventional covid therapies, increasing demand for digestive and immune health remedies.
The rising demand for herbal medicine is expected to drive the growth of the Huoxiang Zhengqi for COVID-19 market in the coming years. Herbal medicine involves the use of plants or plant-derived substances for therapeutic purposes to prevent, treat, or manage health conditions. This growing demand is largely fueled by consumers’ preference for natural, plant-based remedies over synthetic drugs, due to perceived safety, fewer side effects, and holistic health benefits. Huoxiang Zhengqi for COVID-19 supports herbal medicine by offering a traditional remedy that enhances immune function, alleviates symptoms, and promotes recovery, highlighting the potential of herbal therapies in managing viral infections. For example, in September 2024, HerbalGram, a US-based nonprofit organization, reported that total annual sales of herbal dietary supplements increased from $12.018 billion in 2022 to $12.551 billion in 2023, reflecting a 4.4% growth. Consequently, the growing demand for herbal medicine is propelling the expansion of the Huoxiang Zhengqi for COVID-19 market.
Leading companies in the Huoxiang Zhengqi for COVID-19 market are focusing on innovative private-brand product launches, such as Huoxiang Zhengqi oral liquid formulations. These modernized liquid versions of the traditional Huoxiang Zhengqi herbal formula are designed to enhance convenience, ensure accurate dosing, and promote faster absorption. For example, in June 2024, YSB Inc., a China-based pharmaceutical retail and healthcare services company, launched the Leyaoshi Huoxiang Zhengqi Oral Liquid. The product features a ready-to-drink, single-dose liquid format, provides rapid digestive and anti-dampness support, and has a formulation optimized for seasonal gastrointestinal discomfort.
In August 2024, China Resources Sanjiu, a China-based provider of traditional Chinese medicines and pharmaceutical products, acquired a 28% stake in Tasly Pharmaceuticals for USD 8.75 billion (RMB 62.12 billion). This acquisition was intended to strengthen the company’s control over Tasly, enhancing its strategic capabilities in modern Chinese medicine innovation and integrated drug development. Tasly Pharmaceuticals is a China-based company specializing in modern traditional Chinese medicines, chemical drugs, and biopharmaceutical therapies.
Major companies operating in the huoxiang zhengqi for COVID-19 market are Yunnan Baiyao Group Co. Ltd., Beijing Tongrentang Co. Ltd., Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd., Tasly Pharmaceutical Group Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Guizhou Sanli Pharmaceutical Co. Ltd., China Shineway Pharmaceutical Group Limited, Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., Wuhu Zhanghengchun Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd., Sichuan Neo-Green Pharmaceutical Technology Co. Ltd., Hutchison China MediTech Limited, Shijiazhuang Yiling Pharmaceutical Co. Ltd., Jilin Aodong Pharmaceutical Group Co. Ltd., Livzon Pharmaceutical Group Inc., China Traditional Chinese Medicine Holdings Co. Ltd., Kunming Pharmaceutical Corp., Guangdong Yifang Pharmaceutical Co. Ltd., Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Asia-Pacific was the largest region in the Huoxiang Zhengqi for COVID-19 market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the huoxiang zhengqi for COVID-19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the huoxiang zhengqi for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the huoxiang zhengqi for COVID-19 market by increasing the cost of imported herbal raw materials, botanical extracts, and packaging components used in traditional formulations. These impacts have been most visible in liquid and granule product segments, particularly in export-driven Asia-Pacific markets. International distribution channels have faced pricing volatility due to trade barriers. However, tariffs have encouraged domestic cultivation of medicinal herbs and localized production, strengthening supply stability.
The huoxiang zhengqi for COVID-19 market research report is one of a series of new reports that provides huoxiang zhengqi for COVID-19 market statistics, including huoxiang zhengqi for COVID-19 industry global market size, regional shares, competitors with a huoxiang zhengqi for COVID-19 market share, detailed huoxiang zhengqi for COVID-19 market segments, market trends and opportunities, and any further data you may need to thrive in the huoxiang zhengqi for COVID-19 industry. This huoxiang zhengqi for COVID-19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Huoxiang Zhengqi for COVID-19 is a traditional Chinese herbal formula used to manage COVID-19 cases, especially when symptoms include gastrointestinal issues such as nausea, diarrhea, or fatigue caused by dampness. Its primary role is to expel dampness, relieve exterior syndromes, and support digestive and immune function. It is often used alongside antiviral and supportive therapies in traditional Chinese medicine protocols.
The main types of Huoxiang Zhengqi for COVID-19 include liquids, pills, granules, and other forms. Huoxiang Zhengqi liquid is designed to relieve digestive symptoms such as nausea, vomiting, and bloating by restoring balance to the stomach and spleen. Its users typically include health-conscious individuals, those seeking immune support, alternative medicine enthusiasts, and parents purchasing for their children. It is commonly applied for preventive health, symptom management during COVID-19, post-recovery care, and seasonal or illness-related protection. The product is used in hospitals, clinics, home care settings, and other healthcare environments.
The huoxiang Zhengqi for COVID-19 market consists of sales of syrups, powders, injections, essential oils, and nasal sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Huoxiang Zhengqi for COVID-19 Market Characteristics
3. Huoxiang Zhengqi for COVID-19 Market Supply Chain Analysis
4. Global Huoxiang Zhengqi for COVID-19 Market Trends and Strategies
5. Huoxiang Zhengqi for COVID-19 Market Analysis of End Use Industries
7. Global Huoxiang Zhengqi for COVID-19 Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Huoxiang Zhengqi for COVID-19 Total Addressable Market (TAM) Analysis for the Market
9. Huoxiang Zhengqi for COVID-19 Market Segmentation
10. Huoxiang Zhengqi for COVID-19 Market Regional and Country Analysis
11. Asia-Pacific Huoxiang Zhengqi for COVID-19 Market
12. China Huoxiang Zhengqi for COVID-19 Market
13. India Huoxiang Zhengqi for COVID-19 Market
14. Japan Huoxiang Zhengqi for COVID-19 Market
15. Australia Huoxiang Zhengqi for COVID-19 Market
16. Indonesia Huoxiang Zhengqi for COVID-19 Market
17. South Korea Huoxiang Zhengqi for COVID-19 Market
18. Taiwan Huoxiang Zhengqi for COVID-19 Market
19. South East Asia Huoxiang Zhengqi for COVID-19 Market
20. Western Europe Huoxiang Zhengqi for COVID-19 Market
21. UK Huoxiang Zhengqi for COVID-19 Market
22. Germany Huoxiang Zhengqi for COVID-19 Market
23. France Huoxiang Zhengqi for COVID-19 Market
24. Italy Huoxiang Zhengqi for COVID-19 Market
25. Spain Huoxiang Zhengqi for COVID-19 Market
26. Eastern Europe Huoxiang Zhengqi for COVID-19 Market
27. Russia Huoxiang Zhengqi for COVID-19 Market
28. North America Huoxiang Zhengqi for COVID-19 Market
29. USA Huoxiang Zhengqi for COVID-19 Market
30. Canada Huoxiang Zhengqi for COVID-19 Market
31. South America Huoxiang Zhengqi for COVID-19 Market
32. Brazil Huoxiang Zhengqi for COVID-19 Market
33. Middle East Huoxiang Zhengqi for COVID-19 Market
34. Africa Huoxiang Zhengqi for COVID-19 Market
36. Huoxiang Zhengqi for COVID-19 Market Competitive Landscape and Company Profiles
37. Huoxiang Zhengqi for COVID-19 Market Other Major and Innovative Companies
40. Huoxiang Zhengqi for COVID-19 Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Huoxiang Zhengqi For COVID-19 Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses huoxiang zhengqi for COVID-19 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for huoxiang zhengqi for COVID-19? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The huoxiang zhengqi for COVID-19 market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Liquid; Pills; Granules; Other Product Types2) By Consumers: Health-Conscious Consumers; Individuals Seeking Immunity Support; Alternative Medicine Enthusiasts; Parents Purchasing For Children
3) By Usage Occasions: Preventive Health Use; During COVID-19 Symptoms; Post-Recovery Health Management; Seasonal Illness Protection
4) By Application: Hospitals; Clinics; Home Care; Other Applications
5) By Distribution Chanel: Online Pharmacies; Retail Pharmacies; Hospital Pharmacies; Other Distribution Chanels
Subsegments:
1) By Liquid: Oral Liquid; Injectable Liquid2) By Pills: Tablets; Capsules
3) By Granules: Single-Dose Granules; Multi-Dose Granules
4) By Other Product Types: Syrup; Powder For Solution
Companies Mentioned: Yunnan Baiyao Group Co. Ltd.; Beijing Tongrentang Co. Ltd.; Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd.; Tasly Pharmaceutical Group Co. Ltd.; Harbin Pharmaceutical Group Co. Ltd.; Guizhou Sanli Pharmaceutical Co. Ltd.; China Shineway Pharmaceutical Group Limited; Zhangzhou Pientzehuang Pharmaceutical Co. Ltd.; Wuhu Zhanghengchun Medicine Co. Ltd.; Tonghua Dongbao Pharmaceutical Co. Ltd.; Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.; Sichuan Neo-Green Pharmaceutical Technology Co. Ltd.; Hutchison China MediTech Limited; Shijiazhuang Yiling Pharmaceutical Co. Ltd.; Jilin Aodong Pharmaceutical Group Co. Ltd.; Livzon Pharmaceutical Group Inc.; China Traditional Chinese Medicine Holdings Co. Ltd.; Kunming Pharmaceutical Corp.; Guangdong Yifang Pharmaceutical Co. Ltd.; Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Huoxiang Zhengqi for Covid 19 market report include:- Yunnan Baiyao Group Co. Ltd.
- Beijing Tongrentang Co. Ltd.
- Taiji Group Chongqing Fuling Pharmaceutical Factory Co. Ltd.
- Tasly Pharmaceutical Group Co. Ltd.
- Harbin Pharmaceutical Group Co. Ltd.
- Guizhou Sanli Pharmaceutical Co. Ltd.
- China Shineway Pharmaceutical Group Limited
- Zhangzhou Pientzehuang Pharmaceutical Co. Ltd.
- Wuhu Zhanghengchun Medicine Co. Ltd.
- Tonghua Dongbao Pharmaceutical Co. Ltd.
- Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
- Sichuan Neo-Green Pharmaceutical Technology Co. Ltd.
- Hutchison China MediTech Limited
- Shijiazhuang Yiling Pharmaceutical Co. Ltd.
- Jilin Aodong Pharmaceutical Group Co. Ltd.
- Livzon Pharmaceutical Group Inc.
- China Traditional Chinese Medicine Holdings Co. Ltd.
- Kunming Pharmaceutical Corp.
- Guangdong Yifang Pharmaceutical Co. Ltd.
- Jiangyin Tianjiang Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.73 Billion |
| Forecasted Market Value ( USD | $ 2.72 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
